Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Por Hu, Jinyang, Xiao, Qungen, Dong, Minhai, Guo, Dongsheng, Wu, Xudong, Wang, Baofeng
Publicado no Front Immunol (2020)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling

Por Xiao, Qungen, Dong, Minhai, Cheng, Fangling, Mao, Feng, Zong, Weifeng, Wu, Kang, Wang, Heping, Xie, Ruifan, Wang, Baofeng, Lei, Ting, Guo, Dongsheng
Publicado no Int J Oncol (2018)

LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling

Por Xiao, Qungen, Dong, Minhai, Cheng, Fangling, Mao, Feng, Zong, Weifeng, Wu, Kang, Wang, Heping, Xie, Ruifan, Wang, Baofeng, Lei, Ting, Guo, Dongsheng
Publicado no Int J Oncol (2019)

The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Por Cheng, Fangling, Zhang, Po, Xiao, Qungen, Li, Youwei, Dong, Minhai, Wang, Heping, Kuang, Dong, He, Yue, Duan, Qiuhong, Mao, Feng, Wang, Baofeng, Guo, Dongsheng
Publicado no Front Oncol (2019)

Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Por Cheng, Fangling, Zhang, Po, Xiao, Qungen, Li, Youwei, Dong, Minhai, Wang, Heping, Kuang, Dong, He, Yue, Duan, Qiuhong, Mao, Feng, Wang, Baofeng, Guo, Dongsheng
Publicado no Front Oncol (2020)